Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethanolamine SCHEMBL1585206 | 1.00 | CA5A (0.47) | CA5ACA5BALDH1A1TDP1LMNA | |
| Diethanolamine SCHEMBL8754524 | 1.00 | CA5A (0.47) | CA5ACA5BALDH1A1TDP1LMNA | |
| Diethanolamine SCHEMBL28193120 | 0.95 | CA5A (0.42) | CA5ACA5BALDH1A1TDP1KMT2A | |
| Diethanolamine SCHEMBL20542044 | 0.88 | ALDH1A1 (0.41) | CA5ACA5BALDH1A1TDP1LMNA | |
| Diethanolamine SCHEMBL8824865 | 0.88 | ALDH1A1 (0.41) | CA5ACA5BALDH1A1TDP1LMNA | |
| Nitric Acid SCHEMBL28326268 | 0.88 | CA5B (0.46) | CA5ACA5BALDH1A1TDP1LMNA | |
| Nitric Acid SCHEMBL30555522 | 0.88 | PAOX (0.38) | CA5ACA5BALDH1A1TDP1 | |
| Nitric Acid SCHEMBL15789388 | 0.85 | CA5A (0.38) | CA5ACA5BALDH1A1TDP1KMT2A | |
| Diethanolamine SCHEMBL8668340 | 0.81 | TSHR (0.55) | ALDH1A1TDP1 | |
| Nitric Acid SCHEMBL27904656 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025151713-A1 | PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250215321-A1 | COMPOSITIONS AND METHODS FOR REDUCING DELETERIOUS ATMOSPHERIC GAS EMISSIONS FROM FLOODED ECOSYSTEMS | Arkea Bio Corp. | 2025-07-03 | — | — | US | claimed |
| WO-2025128700-A1 | CELL-BASED VACCINES | Arkea Bio Corp. (US) | 2025-06-19 | — | — | WO | claimed |
| EP-4554616-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025056754-A1 | POWDEROUS FORMULATIONS | DSM IP ASSETS B.V. (NL) | 2025-03-20 | — | — | WO | claimed |
| WO-2025006966-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF LIVESTOCK WATER SUPPLY TO REDUCE DELETERIOUS ATMOSPHERIC GAS EMISSIONS | Arkea Bio Corp. (US) | 2025-01-02 | — | — | WO | claimed |
| CN-113163804-B | Adsorbate(s) | 帝斯曼知识产权资产管理有限公司 | 2024-07-02 | — | — | CN | claimed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | claimed |
| EP-4302609-A2 | CONTINUOUS PRODUCTION OF AN ADSORPTION PRODUCT OF A NITROOXY-FUNCTIONAL ORGANIC COMPOUND | DSM IP Assets B.V. (NL) | 2024-01-10 | — | — | EP | claimed |
| WO-2018149756-A1 | STORAGE-STABLE FORMULATIONS | DSM IP ASSETS B.V. (NL) | 2018-08-23 | — | — | WO | claimed |
| WO-2018091643-A1 | POWDEROUS FORMULATIONS | DSM IP ASSETS B.V. (NL) | 2018-05-24 | — | — | WO | claimed |
| EP-3238720-A1 | ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF | DSM IP Assets B.V. (NL) | 2017-11-01 | — | — | EP | claimed |
| WO-2017137489-A1 | ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF | DSM IP ASSETS B.V. (NL) | 2017-08-17 | — | — | WO | claimed |
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2013-12-19 | — | — | US | claimed |
| EP-2665472-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | Solvotrin Innovations Limited (IE) | 2013-11-27 | — | — | EP | claimed |
| WO-2012076667-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2012-06-14 | — | — | WO | claimed |
| CN-86100451-B | Solid gas generating agent with small burning speed and pressure response | 华东工学院 | 1988-03-09 | — | — | CN | claimed |
| US-4718954-A | OXIDIZER, SENSITIZER, GEL | THERMEX ENERGY CORPORATION (US) | 1988-01-12 | — | — | US | claimed |
| CN-86100451-A | The novel solid gas generator propellant that burning is little | — | 1987-08-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | MMP9, NOS2, MMP1 | CA5A 367/4885CA5B 197/4885ALDH1A1 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.